Fudarabine/cyclophosphamide followed by allogeneic peripheral blood transplantation (pbct) for older patients with advanced hematological disorders

Choon Kee Lee, Raymond Hohl, Annette Schlueter, Masaki Hayashi, Elizabeth Field, Roger D. Gingrich

Research output: Contribution to journalArticle

Abstract

The use of allogeneic stem cell transplantation is usually restricted to patients (pts) younger than 55 years of age due to the excessive transplant related mortality (TRM) observed in older pts. The low risk of TRM from non-myeloablative transplants makes the procedure applicable to older pts. Here we report 9 pts with a median age of 61 years (range 57 to 67) who underwent conditioning with fludarabine 25mg/m2x3 days and cyclophosphamide 750mg/nvx 3days followed by PBCT from a G-CSF stimulated HLA identical sibling donor. As GVHD prophylaxis 6 pts received cyclosporin (CSA) and mini-dose methotrexate, 2 pts CSA and mycophenolate mofetyl and 1 pt CSA and prednisone. CSA was given until day 60 then tappered off if no GVHD occured. All pts received low dose amphotericin B at 0.3mg/Kg as antifungal prophylaxis during neutropenia, CMV prophylaxis with gancyclovir and PCP prophylaxis. Diagnosis included secondary AML in 2 pts, multiple myeloma in 1 pt. CML in accelerated phase in Ipt, AL amyloid in 1 pt, mantle cell lymphoma in Ipt, secondary MDS in Ipt, NK leukemia in 1 pt and chronic myelomonocytic leukemia in another. There were 3 females and 6 males. Two pts had previous transplants (1 allogeneic and ! autologous). Only one pt was in CR at time of therapy. Median transplant dose was 5.2x10" CD34+cells/Kg and 2.2x10" CD3+cells/Kg. Severe mucositis and VOD did not occur. The pt with amyloid experienced acute renal failure requiring dialysis. Hématologie nadirs were brief with a median time to ANC>0.5xlO /L of 10 days (range 7 to 17) and a platlet count > 20xlO'/L of 11 days (range 6 to 13). Six pts experienced grade III-1V acute GVHD. GVHD contributed to the death of 3 pts. One pt has chronic GVHD. Seven pts survived more than 28 days. Two early deaths were caused by disseminated aspergillosis in 1 pt and engraftment syndrome in another. One pt with multiple myeloma died of disease progression . Three pts are alive at +15, +12, +6 months. All are in CR. We conclude that this approach seems feasible in an older population. Modifications are needed to reduce the incidence of GVHD.

Original languageEnglish (US)
JournalBlood
Volume96
Issue number11 PART II
StatePublished - Dec 1 2000

Fingerprint

Transplants
Cyclophosphamide
Blood
Transplantation
Amyloid
Emitter coupled logic circuits
Ganciclovir
Dialysis
Amphotericin B
Granulocyte Colony-Stimulating Factor
Prednisone
Stem cells
Methotrexate
Cyclosporine
Multiple Myeloma
Leukemia, Myelomonocytic, Chronic
Mantle-Cell Lymphoma
Mucositis
Aspergillosis
Mortality

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Lee, Choon Kee ; Hohl, Raymond ; Schlueter, Annette ; Hayashi, Masaki ; Field, Elizabeth ; Gingrich, Roger D. / Fudarabine/cyclophosphamide followed by allogeneic peripheral blood transplantation (pbct) for older patients with advanced hematological disorders. In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{105ceeabdda5443fbe63fef2b88373dc,
title = "Fudarabine/cyclophosphamide followed by allogeneic peripheral blood transplantation (pbct) for older patients with advanced hematological disorders",
abstract = "The use of allogeneic stem cell transplantation is usually restricted to patients (pts) younger than 55 years of age due to the excessive transplant related mortality (TRM) observed in older pts. The low risk of TRM from non-myeloablative transplants makes the procedure applicable to older pts. Here we report 9 pts with a median age of 61 years (range 57 to 67) who underwent conditioning with fludarabine 25mg/m2x3 days and cyclophosphamide 750mg/nvx 3days followed by PBCT from a G-CSF stimulated HLA identical sibling donor. As GVHD prophylaxis 6 pts received cyclosporin (CSA) and mini-dose methotrexate, 2 pts CSA and mycophenolate mofetyl and 1 pt CSA and prednisone. CSA was given until day 60 then tappered off if no GVHD occured. All pts received low dose amphotericin B at 0.3mg/Kg as antifungal prophylaxis during neutropenia, CMV prophylaxis with gancyclovir and PCP prophylaxis. Diagnosis included secondary AML in 2 pts, multiple myeloma in 1 pt. CML in accelerated phase in Ipt, AL amyloid in 1 pt, mantle cell lymphoma in Ipt, secondary MDS in Ipt, NK leukemia in 1 pt and chronic myelomonocytic leukemia in another. There were 3 females and 6 males. Two pts had previous transplants (1 allogeneic and ! autologous). Only one pt was in CR at time of therapy. Median transplant dose was 5.2x10{"} CD34+cells/Kg and 2.2x10{"} CD3+cells/Kg. Severe mucositis and VOD did not occur. The pt with amyloid experienced acute renal failure requiring dialysis. H{\'e}matologie nadirs were brief with a median time to ANC>0.5xlO /L of 10 days (range 7 to 17) and a platlet count > 20xlO'/L of 11 days (range 6 to 13). Six pts experienced grade III-1V acute GVHD. GVHD contributed to the death of 3 pts. One pt has chronic GVHD. Seven pts survived more than 28 days. Two early deaths were caused by disseminated aspergillosis in 1 pt and engraftment syndrome in another. One pt with multiple myeloma died of disease progression . Three pts are alive at +15, +12, +6 months. All are in CR. We conclude that this approach seems feasible in an older population. Modifications are needed to reduce the incidence of GVHD.",
author = "Lee, {Choon Kee} and Raymond Hohl and Annette Schlueter and Masaki Hayashi and Elizabeth Field and Gingrich, {Roger D.}",
year = "2000",
month = "12",
day = "1",
language = "English (US)",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

Fudarabine/cyclophosphamide followed by allogeneic peripheral blood transplantation (pbct) for older patients with advanced hematological disorders. / Lee, Choon Kee; Hohl, Raymond; Schlueter, Annette; Hayashi, Masaki; Field, Elizabeth; Gingrich, Roger D.

In: Blood, Vol. 96, No. 11 PART II, 01.12.2000.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fudarabine/cyclophosphamide followed by allogeneic peripheral blood transplantation (pbct) for older patients with advanced hematological disorders

AU - Lee, Choon Kee

AU - Hohl, Raymond

AU - Schlueter, Annette

AU - Hayashi, Masaki

AU - Field, Elizabeth

AU - Gingrich, Roger D.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - The use of allogeneic stem cell transplantation is usually restricted to patients (pts) younger than 55 years of age due to the excessive transplant related mortality (TRM) observed in older pts. The low risk of TRM from non-myeloablative transplants makes the procedure applicable to older pts. Here we report 9 pts with a median age of 61 years (range 57 to 67) who underwent conditioning with fludarabine 25mg/m2x3 days and cyclophosphamide 750mg/nvx 3days followed by PBCT from a G-CSF stimulated HLA identical sibling donor. As GVHD prophylaxis 6 pts received cyclosporin (CSA) and mini-dose methotrexate, 2 pts CSA and mycophenolate mofetyl and 1 pt CSA and prednisone. CSA was given until day 60 then tappered off if no GVHD occured. All pts received low dose amphotericin B at 0.3mg/Kg as antifungal prophylaxis during neutropenia, CMV prophylaxis with gancyclovir and PCP prophylaxis. Diagnosis included secondary AML in 2 pts, multiple myeloma in 1 pt. CML in accelerated phase in Ipt, AL amyloid in 1 pt, mantle cell lymphoma in Ipt, secondary MDS in Ipt, NK leukemia in 1 pt and chronic myelomonocytic leukemia in another. There were 3 females and 6 males. Two pts had previous transplants (1 allogeneic and ! autologous). Only one pt was in CR at time of therapy. Median transplant dose was 5.2x10" CD34+cells/Kg and 2.2x10" CD3+cells/Kg. Severe mucositis and VOD did not occur. The pt with amyloid experienced acute renal failure requiring dialysis. Hématologie nadirs were brief with a median time to ANC>0.5xlO /L of 10 days (range 7 to 17) and a platlet count > 20xlO'/L of 11 days (range 6 to 13). Six pts experienced grade III-1V acute GVHD. GVHD contributed to the death of 3 pts. One pt has chronic GVHD. Seven pts survived more than 28 days. Two early deaths were caused by disseminated aspergillosis in 1 pt and engraftment syndrome in another. One pt with multiple myeloma died of disease progression . Three pts are alive at +15, +12, +6 months. All are in CR. We conclude that this approach seems feasible in an older population. Modifications are needed to reduce the incidence of GVHD.

AB - The use of allogeneic stem cell transplantation is usually restricted to patients (pts) younger than 55 years of age due to the excessive transplant related mortality (TRM) observed in older pts. The low risk of TRM from non-myeloablative transplants makes the procedure applicable to older pts. Here we report 9 pts with a median age of 61 years (range 57 to 67) who underwent conditioning with fludarabine 25mg/m2x3 days and cyclophosphamide 750mg/nvx 3days followed by PBCT from a G-CSF stimulated HLA identical sibling donor. As GVHD prophylaxis 6 pts received cyclosporin (CSA) and mini-dose methotrexate, 2 pts CSA and mycophenolate mofetyl and 1 pt CSA and prednisone. CSA was given until day 60 then tappered off if no GVHD occured. All pts received low dose amphotericin B at 0.3mg/Kg as antifungal prophylaxis during neutropenia, CMV prophylaxis with gancyclovir and PCP prophylaxis. Diagnosis included secondary AML in 2 pts, multiple myeloma in 1 pt. CML in accelerated phase in Ipt, AL amyloid in 1 pt, mantle cell lymphoma in Ipt, secondary MDS in Ipt, NK leukemia in 1 pt and chronic myelomonocytic leukemia in another. There were 3 females and 6 males. Two pts had previous transplants (1 allogeneic and ! autologous). Only one pt was in CR at time of therapy. Median transplant dose was 5.2x10" CD34+cells/Kg and 2.2x10" CD3+cells/Kg. Severe mucositis and VOD did not occur. The pt with amyloid experienced acute renal failure requiring dialysis. Hématologie nadirs were brief with a median time to ANC>0.5xlO /L of 10 days (range 7 to 17) and a platlet count > 20xlO'/L of 11 days (range 6 to 13). Six pts experienced grade III-1V acute GVHD. GVHD contributed to the death of 3 pts. One pt has chronic GVHD. Seven pts survived more than 28 days. Two early deaths were caused by disseminated aspergillosis in 1 pt and engraftment syndrome in another. One pt with multiple myeloma died of disease progression . Three pts are alive at +15, +12, +6 months. All are in CR. We conclude that this approach seems feasible in an older population. Modifications are needed to reduce the incidence of GVHD.

UR - http://www.scopus.com/inward/record.url?scp=33748542932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748542932&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748542932

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -